Share information
271.80 €
+1.49 %
09/04/2026 17:36
+1.49 %
Open
High
Low
Volume
267.60 €
271.80 €
263.60 €
197,049
Latest News
03-Apr-2026
Acquisition of own shares
31-Mar-2026
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)
27-Mar-2026
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa
27-Mar-2026
UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis